scholarly journals GEOGRAPHIC DISPARITIES IN COUNTY-LEVEL PREVALENCE OF ALZHEIMER’S DISEASE ACROSS THE UNITED STATES

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S782-S782 ◽  
Author(s):  
Mackenzie E Fowler ◽  
Christina DiBlasio ◽  
Michael Crowe ◽  
Richard E Kennedy
Keyword(s):  
United States ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Small Area ◽  
Empirical Bayes ◽  
Local Population ◽  
The United States ◽  
County Level ◽  
Prevalence Rates ◽  
Geographic Disparities

Abstract Small-area geographic disparities in health care delivery have been observed across multiple disorders, but remain poorly studied for Alzheimer’s disease (AD) and other dementias. While national and state estimates of the prevalence and incidence of AD are available, estimates across finer geographic regions offer an opportunity to tailor programs to the needs of the local population. We estimated prevalence of AD at the county level across the continental United States. We used prevalence rates of AD by age category and race among Medicare fee-for-service beneficiaries published by the Centers for Disease Control (CDC). These prevalence rates were projected onto bridged-race county-level population data for 2017 from the National Center for Health Statistics, with empirical Bayes spatial smoothing to reduce variability in rates due to small population sizes. Estimated prevalence of AD varied more than threefold across counties, from a low of 51.8 per 1,000 persons in Loving County, Texas to a high of 169.6 per 1,000 persons in Kalawao County, Hawaii. Higher prevalence of AD was seen in the Southeastern and Midwestern United States. However, we observed specific counties with low prevalence of AD within regions with high prevalence of AD, and vice versa. These small-area geographic variations may provide vital information about social and environmental influences on dementia care, yet little data have been available to date. Understanding geographic disparities in prevalence will be critical for addressing practice variation in the prevention and diagnosis of dementia.

scholarly journals Geographic Disparities in County-Level Prevalence of Alzheimer’s Disease Across the United States

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 851-851
Author(s):  
Mackenzie Fowler ◽  
Michael Crowe ◽  
Richard Kennedy
Keyword(s):  
United States ◽  
Racial Differences ◽  
Local Population ◽  
The United States ◽  
Practice Variation ◽  
County Level ◽  
Geographic Disparities ◽  
Explanatory Factors ◽  
Diagnosis Of Dementia ◽  
National And State Estimates

Abstract While national and state estimates of the prevalence and incidence of AD are available, estimates across finer geographic regions offer an opportunity to tailor programs to the needs of the local population. Previously, we estimated prevalence and incidence of AD at the county level across the continental United States and found that estimated prevalence of AD varied more than threefold across counties, predominantly in the Southeastern and Midwestern United States. We also observed “islands” of low AD within regions with high AD, and vice versa. We update these findings by examining changes in projected prevalence of AD over time, and comparing projected prevalence of AD to prevalence of AD diagnoses in Medicare. We also examine regional variation in provider specialty patterns and racial differences across counties as possible explanatory factors. Understanding small-area geographic disparities in prevalence will be critical for addressing practice variation in the prevention and diagnosis of dementia.

Leveraging Technology in Detection of Alzheimer’s Disease: A Systematic Review (Preprint)

2019 ◽  
Author(s):  
Clemens Kruse ◽  
Britney Larson ◽  
Reagan Wilkinson ◽  
Roger Samson ◽  
Taylor Castillo
Keyword(s):  
Magnetic Resonance Imaging ◽  
United States ◽  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
The United States ◽  
Diagnostic Process ◽  
Resonance Imaging ◽  
Common Cause ◽  
Key Terms

BACKGROUND Incidence of AD continues to increase, making it the most common cause of dementia and the sixth-leading cause of death in the United States. 2018 numbers are expected to double by 2030. OBJECTIVE We examined the benefits of utilizing technology to identify and detect Alzheimer’s disease in the diagnostic process. METHODS We searched PubMed and CINAHL using key terms and filters to identify 30 articles for review. We analyzed these articles and reported them in accordance with the PRISMA guidelines. RESULTS We identified 11 technologies used in the detection of Alzheimer’s disease: 66% of which used some form of MIR. Functional, structural, and 7T magnetic resonance imaging were all used with structural being the most prevalent. CONCLUSIONS MRI is the best form of current technology being used in the detection of Alzheimer’s disease. MRI is a noninvasive approach that provides highly accurate results in the diagnostic process of Alzheimer’s disease.

380 Projected incidence of Alzheimer's disease in the United States

1996 ◽  
Vol 17 (4) ◽  
pp. S95
Author(s):  
L. Hebert ◽  
P. Scherr ◽  
L. Beckett ◽  
D. Evans
Keyword(s):  
United States ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
The United States

scholarly journals Deaths in the United States among persons with Alzheimer's disease (2010-2050)

2014 ◽  
Vol 10 (2) ◽  
pp. e40-e46 ◽  
Author(s):  
Jennifer Weuve ◽  
Liesi E. Hebert ◽  
Paul A. Scherr ◽  
Denis A. Evans
Keyword(s):  
United States ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
The United States

United States

2019 ◽  
pp. 305-312
Author(s):  
Angela M Lunde ◽  
Ronald C Petersen ◽  
John A Lucas
Keyword(s):  
United States ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Research Funding ◽  
Public Awareness ◽  
The United States ◽  
Care Quality ◽  
National Plan ◽  
Genetic Studies ◽  
Number Of Treatment

In the United States, the National Alzheimer’s Project Act was signed into law in January 2011, and the first National Plan appeared just over 12 months later, with five goals: to prevent and effectively treat Alzheimer’s disease by 2025, to enhance care quality and efficiency, to expand support for people with Alzheimer’s disease and their families, to enhance public awareness and engagement, and to improve data to track progress. The National Plan has seen a rise in research funding (currently standing at US$1.4 billion). Individual states, at the same time, began discussions about initiatives aimed at addressing personal, societal, and financial implications of Alzheimer’s disease. An example is from Minnesota where counselling and support for caregivers are provided, with an estimated saving for the state of Minnesota of US$970 million by 2025. In addition, a number of treatment trials are under way, looking at the effect of monoclonal antibodies on Alzheimer’s disease and a series of genetic studies.

scholarly journals PND57 THE SOCIETAL BURDEN OF PRODROMAL ALZHEIMER’S DISEASE IN THE UNITED STATES

2019 ◽  
Vol 22 ◽  
pp. S280
Author(s):  
K. Saxena ◽  
J. Sullivan ◽  
R. Khandker ◽  
A.S. Ward ◽  
C. Black ◽  
...  
Keyword(s):  
United States ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
The United States ◽  
Societal Burden ◽  
Prodromal Alzheimer’S Disease

Agitation in Demented Patients in the United States

1997 ◽  
Vol 8 (S3) ◽  
pp. 487-490 ◽  
Author(s):  
Jacobo E. Mintzer ◽  
Paul Nietert ◽  
Kerri Costa ◽  
L. Randolph Waid
Keyword(s):  
United States ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Ethnic Groups ◽  
The United States ◽  
Behavioral Disturbances ◽  
Dementing Disorders

Alzheimer's disease and other dementing disorders have been reported in most ethnic groups living in the United States. Although the presence of these disorders in different U.S. ethnic groups is well documented, the characteristics of dementing disorders, such as the presence of behavioral disturbances, in these groups remains unexplored.

Sign in / Sign up

Export Citation Format

Share Document